Optimizing PCP therapy.
Torres
G
G
Cadman
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control; D000336:Aerosols; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004660:Encephalitis / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D009285:Naphthoquinones / Q000627:therapeutic use; D010419:Pentamidine / Q000008:administration & dosage / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000517:prevention & control; D014123:Toxoplasmosis / Q000188:drug therapy / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use*
D000336:Aerosols; D000935:Antifungal Agents; D009285:Naphthoquinones; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D053626:Atovaquone